voxelotor

Global Blood Therapeutics Inc (NASDAQ: GBT) shares were trading down off the open Wednesday after the company released data from its sickle cell disease candidate. What Happened Part A of a Phase 3 study of voxelotor in sickle cell disease achieved the primary endpoints, the company said. ...

Multiple small- and mid-cap biotech stocks have benefited from a strong run, prompting Morgan Stanley to downgrade three companies in the group. The Analyst Morgan Stanley's Matthew Harrison downgraded the following: Sarepta Therapeutics Inc (NASDAQ: SRPT) from Overweight to Sector Weight...

Global Blood Therapeutics Inc (NASDAQ: GBT), a clinical-stage biopharmaceutical company that develops therapeutics to treat blood-based disorders, received a breakthrough therapy designation in early January that has at least one analyst optimistic as to what will come next. The Analyst William...